Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
about
Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistanceResistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsInterferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug ResistanceHepatitis C virus molecular evolution: transmission, disease progression and antiviral therapyPotential Antivirals: Natural Products Targeting Replication Enzymes of Dengue and Chikungunya Viruses.Antiviral natural products and herbal medicines.Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve PatientsAntiviral drug resistance as an adaptive processHepatitis C virus NS5A inhibitors and drug resistance mutations.Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.The flavivirus protease as a target for drug discovery.Identification of covalent active site inhibitors of dengue virus protease.A Schisandra-Derived Compound Schizandronic Acid Inhibits Entry of Pan-HCV Genotypes into Human HepatocytesNaturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.Biomedical Mutation Analysis (BMA): A software tool for analyzing mutations associated with antiviral resistanceTreatment for hepatocellular carcinoma in elderly patients: a literature reviewWest Nile virus drug discovery.Antiviral drug discovery: broad-spectrum drugs from nature.Simeprevir: a review of its use in patients with chronic hepatitis C virus infection.AVPdb: a database of experimentally validated antiviral peptides targeting medically important viruses.Hepatitis C virus drug resistance-associated substitutions: State of the art summary.Overcoming drug resistance in HSV, CMV, HBV and HCV infection.The role of HCV proteins on treatment outcomes.New developments in flavivirus drug discovery.Prevention and management of treatment failure to new oral hepatitis C drugs.Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold.Characterization of clinical predictors of naturally occurring NS3/NS4A protease polymorphism in genotype 1 hepatitis C virus mono and HIV co-infected patients.Novel strategies for discovering inhibitors of Dengue and Zika fever.HCV replication in gastrointestinal mucosa: Potential extra-hepatic viral reservoir and possible role in HCV infection recurrence after liver transplantation.Naturally occurring hepatitis C virus protease inhibitors resistance-associated mutations among chronic hepatitis C genotype 1b patients with or without HIV co-infection.The unexpected structures of hepatitis C virus envelope proteinsA plant-derived dehydrorotenoid: a new inhibitor of hepatitis C virus entry.Human monoclonal antibodies as a new class of antiinfective compounds.Flavonoids from Pterogyne nitens Inhibit Hepatitis C Virus Entry.Quasispecies and Drug ResistanceBaseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the approach
P2860
Q26740219-4D1805C9-544A-40D2-BA0D-936AE917E791Q26777408-A8DE147D-4AFB-4E25-95D2-DAEAC9C25E70Q26781331-C7C50064-FD71-4966-A58B-446BB9AC5850Q26853500-D9D6D0E9-7043-42AF-AE24-B2FC63053305Q30400192-2EB9E9E1-3183-4B8A-9913-2E7B1C7928B8Q33657624-4F330C0D-53E6-4C66-855C-3C42C701367FQ33875539-C66215EA-8D7A-442A-A0E9-379F56044A26Q33878407-3ACD2991-6A69-4AB1-B0C3-C2D0F39B4B65Q34411617-991567E9-FFE2-4245-BA4F-F72D86DDAF9AQ34599453-E7E32B98-5036-49EA-BB6D-8883584FD089Q34657530-A82BEB43-89B7-4DE0-8BC2-3DA3A079EB89Q35871359-0346FDB3-1EC1-460C-A258-35101388F96FQ36037497-EF1C5D44-AA27-4263-B38E-42DE15589C28Q36292486-64C24C9E-8ED9-4D3C-B1FE-9914B965DF6AQ36531731-D911F45F-30B7-4681-B68D-23969737D919Q37174078-CBB66FDF-AEFB-4C05-A654-E2E0E6F976A3Q37249500-C1B4D620-DEBA-41F1-B2DD-8AF941850711Q37666750-01EBDC07-10AE-46BA-8A1E-FE7006CA730BQ38260235-D55C859A-9446-470A-8CAE-668356D1D067Q38307580-DB2F3FEA-D508-46AB-94AC-B7814451ACA9Q38490669-2D2002FD-3FCB-4715-AA11-CD3CE6F1F283Q38533619-C9DA6E2F-B51C-4223-8AE7-ABAEEC655DDDQ38622013-051AB3C9-B196-41AB-BA6C-55EF3CFDB3C6Q38668968-43BDD9BE-A7A0-49BA-B62C-9C93FB118266Q38769771-4A5FA973-BBDA-41F5-B44D-37ADF0ECF407Q38826624-D0400BC7-293A-4652-BF8B-49F5BFDCC892Q38885160-46914364-6593-448C-99C6-17CA4E61C6E3Q39182744-FD75C83F-E952-4C46-AE8A-42B20D09DBC5Q40056862-749567F5-93D0-4F6A-9864-0FE5AC82628BQ40105724-275FBC49-65C2-41AF-B483-A77499CA2E52Q41007229-72AF0160-B809-4DB7-8400-E2203D6359DCQ41672624-2CFD2BC5-DB21-4711-8940-8ACA876E05CEQ41981846-2F9FC68E-F5E3-4039-8624-AA8E5F9BAF67Q42113395-69D9A848-9BF4-4330-8D37-D5DADF5AF853Q45324327-A9AFDA4D-2F9E-4A49-B476-528178E9057EQ56957250-CE78B46A-7497-4B4C-A7F2-8D17233D416FQ57482963-DB1B304C-9E14-40FC-B35D-403EF5E2F68C
P2860
Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
@en
type
label
Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
@en
prefLabel
Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
@en
P2860
P356
P1476
Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
@en
P2860
P356
10.1093/INFDIS/JIS761
P407
P478
207 Suppl 1
P577
2013-03-01T00:00:00Z